Delivery Order SPE2DB24D8002-SPE2DB25FJMYN
Award Date
1/10/25
Potential Completion Date
1/13/25
Potential Value
$5.5K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,341.90, is for the delivery of ELIQUIS 2.5 MG TABLET 60S and has a firm fixed price pricing type. The contract has an ultimate completion date of January 16, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal government, with a focus on...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of ELIQUIS 5 MG TABLET 60S. The contract has a ceiling value of $4,296.29 and a period of performance through February 1, 2024. The contract is a firm fixed-price delivery order, and there is no set-aside designation. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,230.88, is for the delivery of 4562802555 ELIQUIS 5 MG TABLET 60S to support military medical operations. Dakota Drug, Inc. holds a large Indefinite Delivery Contract (IDC) with the DLA, worth up to $999,999,999.00, which allows the company to provide a wide range of pharmaceutical products, medical...
This is a Firm Fixed Price Delivery Order awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $7,624.29 contract is for the delivery of 4564885398 units of the pharmaceutical product ELIQUIS 5 MG TABLET 60S. The Delivery Order has a period of performance through June 13, 2024. Dakota Drug, Inc. holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, identified as SPE2DX15D8002|SPE2DX24F2VB1, is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has a ceiling value of $6,246.23 and a period of performance through February 22, 2024. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, holding a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,857.60, is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, to support the DLA Troop Support Medical's medical supply chain operations. The contract has a period of performance through May 30, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of ELIQUIS 5 MG TABLET 60S. The contract, with a ceiling value of $4,973.50 and a performance period extending through October 30, 2024, is a firm fixed-price delivery order. It is not associated with any set-aside program. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,782.06, is for the delivery of ELIQUIS 5 MG TABLET 60S to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, that allows the company to provide a comprehensive range of pharmaceutical products, medical...
This contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, is for the delivery of ELIQUIS 5 MG TABLET 60S to the Defense Logistics Agency (DLA). The firm-fixed-price delivery order, valued at $1,481.53, has an ultimate completion date of February 12, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This IDC, part of the DLA Troop Support Medical's ECAT...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of ELIQUIS 5 MG TABLET 60S. The contract has a ceiling value of $7,379.52 and a performance period ending on November 2, 2023. The contract is an unrestricted, non-set-aside award and is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This IDC,...